An­a­lysts ques­tion Karyophar­m's PhI­II en­dome­tri­al can­cer da­ta as biotech will charge ahead to FDA

Karyopharm Ther­a­peu­tics tout­ed on Tues­day Phase III da­ta for a can­cer pro­gram it de­scribed as pos­i­tive, but which Wall Street viewed in a more neg­a­tive light.

The biotech re­port­ed topline re­sults for Xpovio’s piv­otal study in en­dome­tri­al can­cer, say­ing the drug re­duced the risk of dis­ease pro­gres­sion or death by 30% com­pared to place­bo. Karyopharm not­ed the pri­ma­ry end­point of me­di­an pro­gres­sion-free sur­vival came in at 5.7 months for the ac­tive arm and 3.8 months in place­bo.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER